Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Launched by UNIVERSITY OF CHICAGO · Dec 8, 2021

Keywords

ClinConnect Summary

The Evaluating Personalized Therapeutics Clinic (PTC) trial is looking at how consultations with a specialized clinic can help people taking multiple medications for conditions like cancer and mental health issues. The goal is to see if these consultations can reduce the chances of experiencing harmful side effects from drug interactions—when medications don't work well together—or from differences in how people’s genes affect their response to drugs. Participants will have their genes tested, which will provide valuable information to help doctors make better decisions about the medications they prescribe. This study is expected to last about nine months.

To be eligible for this trial, participants need to be at least 18 years old and receiving care from a doctor at the University of Chicago Medical Center. They should be taking five or more medications, including one that has specific genetic information linked to it. However, individuals who are considering or have already had a liver or kidney transplant, those who are already involved in another similar study, or those who have previously had genetic testing done elsewhere will not be able to participate. The trial welcomes individuals of all backgrounds and genders, and it aims to ensure that everyone has access to the potential benefits of personalized medicine.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult participants cared for by a participating provider at University of Chicago Medical Center.
• • 2. Participants must be at least 18 years of age.
• • 3. Participants prescribed 5 or medication medications and taking a perpetrator drug or a drug with actionable pharmacogenomic information.
• • Exclusion Criteria for Participants
• • 1. Participants who have undergone, or are being actively considered for, liver or kidney transplantation.
• • 2. Participation in another pharmacogenomic study.
• • 3. Participants who have previously received genotyping from another source.
• • 4. Inability to understand and give informed consent to participate.
• • Inclusion of Women, Minorities, and Other Underrepresented Populations Individuals of all races and ethnic groups and genders are eligible for this trial.